Raoul Schendel
@raoullucas.bsky.social
Official Title
A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID
According to ClinicalTrials, 208 patients are planned to be recruited at four centres in the US.
A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID
According to ClinicalTrials, 208 patients are planned to be recruited at four centres in the US.
March 2, 2025 at 12:14 PM
Official Title
A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID
According to ClinicalTrials, 208 patients are planned to be recruited at four centres in the US.
A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID
According to ClinicalTrials, 208 patients are planned to be recruited at four centres in the US.
A new phase II RCT for #LongCOVID / #PostCOVID in the US by the company BioVie with their drug Bezisterim.
clinicaltrials.gov/study/NCT068...
Bezisterim is currently also being studied in Alzheimer’s and Parkinson’s. This is what it says on BioVie’s website about their LC trial.
clinicaltrials.gov/study/NCT068...
Bezisterim is currently also being studied in Alzheimer’s and Parkinson’s. This is what it says on BioVie’s website about their LC trial.
March 2, 2025 at 12:13 PM
A new phase II RCT for #LongCOVID / #PostCOVID in the US by the company BioVie with their drug Bezisterim.
clinicaltrials.gov/study/NCT068...
Bezisterim is currently also being studied in Alzheimer’s and Parkinson’s. This is what it says on BioVie’s website about their LC trial.
clinicaltrials.gov/study/NCT068...
Bezisterim is currently also being studied in Alzheimer’s and Parkinson’s. This is what it says on BioVie’s website about their LC trial.
Am UK Hamburg-Eppendorf (UKE) wird eine Studie zur Diagnoselatenz bei #MECFS und #PostCOVID / #LongCOVID vom Innovationsausschuss des G-BA mit 1,2 Mio. Euro gefördert.
Projektleiterin ist Frau Dr. Christine Blome.
www.uke.de/allgemein/pr...
Projektleiterin ist Frau Dr. Christine Blome.
www.uke.de/allgemein/pr...
September 16, 2024 at 8:42 AM
Am UK Hamburg-Eppendorf (UKE) wird eine Studie zur Diagnoselatenz bei #MECFS und #PostCOVID / #LongCOVID vom Innovationsausschuss des G-BA mit 1,2 Mio. Euro gefördert.
Projektleiterin ist Frau Dr. Christine Blome.
www.uke.de/allgemein/pr...
Projektleiterin ist Frau Dr. Christine Blome.
www.uke.de/allgemein/pr...
Argenx just issued a press release in which it says that the company will not advance development of #Efgartigimod in #LongCOVID / #PostCOVID - #POTS based on Phase 2 ALPHA data.
www.argenx.com/news/argenx-...
www.argenx.com/news/argenx-...
June 17, 2024 at 5:23 AM
Argenx just issued a press release in which it says that the company will not advance development of #Efgartigimod in #LongCOVID / #PostCOVID - #POTS based on Phase 2 ALPHA data.
www.argenx.com/news/argenx-...
www.argenx.com/news/argenx-...
Recruitment for the phase II trial with #BC007 for #LongCOVID now appears to be complete.
clinicaltrials.gov/study/NCT059...
clinicaltrials.gov/study/NCT059...
April 20, 2024 at 10:19 AM
Recruitment for the phase II trial with #BC007 for #LongCOVID now appears to be complete.
clinicaltrials.gov/study/NCT059...
clinicaltrials.gov/study/NCT059...
Vier neue Studienzentren in DE für die Phase II-Studie mit #BC007 zu #LongCOVID wurden heute auf ClinicalTrials hinzugefügt.
clinicaltrials.gov/study/NCT059...
clinicaltrials.gov/study/NCT059...
April 3, 2024 at 1:25 PM
Vier neue Studienzentren in DE für die Phase II-Studie mit #BC007 zu #LongCOVID wurden heute auf ClinicalTrials hinzugefügt.
clinicaltrials.gov/study/NCT059...
clinicaltrials.gov/study/NCT059...
Die Ein- und Ausschlusskriterien der klinischen Phase II-Studie mit #BC007 zu #LongCOVID wurden im EU ClinicalTrialsRegister aktualisiert.
Die initiale COVID-Infektion kann jetzt auch länger als 12 Monate zurückliegen.
www.clinicaltrialsregister.eu/ctr-search/t...
Die initiale COVID-Infektion kann jetzt auch länger als 12 Monate zurückliegen.
www.clinicaltrialsregister.eu/ctr-search/t...
December 19, 2023 at 4:42 PM
Die Ein- und Ausschlusskriterien der klinischen Phase II-Studie mit #BC007 zu #LongCOVID wurden im EU ClinicalTrialsRegister aktualisiert.
Die initiale COVID-Infektion kann jetzt auch länger als 12 Monate zurückliegen.
www.clinicaltrialsregister.eu/ctr-search/t...
Die initiale COVID-Infektion kann jetzt auch länger als 12 Monate zurückliegen.
www.clinicaltrialsregister.eu/ctr-search/t...
BerlinCures just issued a press release about the expansion of their phase II clinical trial with #BC007 for #LongCOVID to five countries across Europe.
In this press release they also share a list of all trial sites which are planned in the near future.
www.businesswire.com/news/home/20...
In this press release they also share a list of all trial sites which are planned in the near future.
www.businesswire.com/news/home/20...
November 23, 2023 at 6:39 AM
BerlinCures just issued a press release about the expansion of their phase II clinical trial with #BC007 for #LongCOVID to five countries across Europe.
In this press release they also share a list of all trial sites which are planned in the near future.
www.businesswire.com/news/home/20...
In this press release they also share a list of all trial sites which are planned in the near future.
www.businesswire.com/news/home/20...
Two clinical centres in Spain have now also started recruiting patients for the phase II trial with #BC007 for #LongCOVID.
www.clinicaltrials.gov/study/NCT059...
www.clinicaltrials.gov/study/NCT059...
November 15, 2023 at 2:19 PM
Two clinical centres in Spain have now also started recruiting patients for the phase II trial with #BC007 for #LongCOVID.
www.clinicaltrials.gov/study/NCT059...
www.clinicaltrials.gov/study/NCT059...
Das Stadtspital Zürich Waid in der Schweiz wird an der Phase II-Studie mit #BC007 zu #LongCOVID teilnehmen.
Laut der Webseite des Spitals wird damit gerechnet, dass ab Herbst/Ende 2023 Patienten in die Studie aufgenommen werden können.
www.stadt-zuerich.ch/waid/de/inde...
Laut der Webseite des Spitals wird damit gerechnet, dass ab Herbst/Ende 2023 Patienten in die Studie aufgenommen werden können.
www.stadt-zuerich.ch/waid/de/inde...
October 1, 2023 at 7:57 PM
Das Stadtspital Zürich Waid in der Schweiz wird an der Phase II-Studie mit #BC007 zu #LongCOVID teilnehmen.
Laut der Webseite des Spitals wird damit gerechnet, dass ab Herbst/Ende 2023 Patienten in die Studie aufgenommen werden können.
www.stadt-zuerich.ch/waid/de/inde...
Laut der Webseite des Spitals wird damit gerechnet, dass ab Herbst/Ende 2023 Patienten in die Studie aufgenommen werden können.
www.stadt-zuerich.ch/waid/de/inde...